Indranil Choudhuri

Indranil Choudhuri

Auto-generated profile, based on publicly available information

Indranil Choudhuri

Department of Biotechnology, PanskuraBanamali College (Autonomous), P.O.-Panskura R.S., West Bengal, India

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

29 January 2022 in Journal of Photochemistry and Photobiology A: Chemistry
Verified
Journal Article
Closed access
PDPranabendu Das
Pranabendu Das
SRSwati Singh Rajput
Swati Singh Rajput
MDManik Das
Manik Das
SLSoumik Laha
Soumik Laha
ICIndranil Choudhuri
Indranil Choudhuri
TMTithi Maity
Tithi Maity

2 May 2022 in Journal of Molecular Structure
Verified
Journal Article
Closed access
SDSusmita Das
Susmita Das
MDManik Das
Manik Das
SLSoumik Laha
Soumik Laha
KRKarunamoy Rajak
Karunamoy Rajak
ICIndranil Choudhuri
Indranil Choudhuri
TMTithi Maity
Tithi Maity

1 July 2024 in Biosciences Biotechnology Research Asia
Verified
Journal Article
Open access
APAnutosh Patra
Anutosh Patra
ICIndranil Choudhuri
Indranil Choudhuri
PPPrasenjit Paria
Prasenjit Paria
ASAbhishek Samanta
Abhishek Samanta
KKKalyani Khanra
Kalyani Khanra
NBNandan Bhattacharyya
Nandan Bhattacharyya
Ovarian cancer poses significant challenges due to limited treatment options and high mortality rates, necessitating innovative therapeutic strategies. Targeting DNA repair pathways, such as DNA polymerase β (Pol β), holds promise for improving treatment outcomes. This study aims to identify phytochemicals from the Super Natural database as natural inhibitors of Pol β activity to enhance ovarian cancer therapy efficacy, particularly when used in combination with damaging agents. Screening a library of 21,105 drug-like molecules alongside 800 compounds from the natural products collection (NatProd, a unique compound library) involved applying Lipinski's Rule of Five, the Golden Triangle rule, and Pfizer’s rule. Following this, compounds predicted to exhibit carcinogenicity, toxicity, and mutagenicity were removed. The outcome of this rigorous screening process yielded 1,104 molecules eligible for structure-based virtual screening. Docking-based virtual screening using two servers was conducted on selected molecules, followed by computer simulations to assess their interaction dynamics and stability with Pol β. Molecular dynamics simulations further evaluated stability and interactions, considering energy, forces, and interaction scores. From these analyses, four promising Pol β inhibitors—SN00158342, SN00305418, SN00004251, and SN00341636—were identified, exhibiting favorable stability profiles, interactions. The binding energiesforSN00158342, SN00305418, SN00004251, and SN00341636 were found to be -22.0327±3.8493, -15.9181±4.5020, -29.7465±6.7833 and -27.3184±5.1579kcal/mol respectively. Utilizing these compounds alongside DNA-damaging agents presents a novel and potentially fruitful approach to improving ovarian cancer treatment outcomes. Overall, this study underscores the potential of phytochemicals as effective Pol β inhibitors, offering a promising avenue for enhancing ovarian cancer therapy effectiveness.